Urology is a specialty under sustained financial pressure from directions that rarely all ease at the same time.
Inflation-adjusted Medicare reimbursement for the most common urologic procedures — prostatectomy, TURBT, cystoscopy — has declined steadily over a 20-year period. Over 60% of U.S. counties have no practicing urologist, creating access gaps that translate to growing patient volumes for those practices that exist. And the 2026 CMS rule introduced a -2.5% efficiency adjustment on work RVUs across nearly every service on the fee schedule — with net projected impact on urology estimated at 0%, masking a +5% gain for office-based services offset by a -10% hit to facility-based services.
In that environment, operational leakage isn't just a financial drag. It's a viability risk.
Urology billing is unusually complex. A single patient visit may involve an E/M service, a diagnostic cystoscopy, a biopsy, a supply code, and a pathology send-out — each with its own CPT logic, modifier requirements, NCCI bundling rules, and medical necessity documentation. Up to 30–40% of urology claims are denied on first submission, and every denied claim costs an average of $25 in rework costs before any revenue recovery is counted.
Here's where the money leaks.
1. The Deleted Prostate Biopsy Code Problem
The single most impactful coding change for urology in 2026 is also one of the most dangerous for practices that haven't fully transitioned: CPT 55700 — the legacy prostate biopsy code — was deleted effective January 1, 2026. It has been replaced by a new family of codes (55707–55715) that bundle imaging guidance and require the biller to distinguish between systematic and targeted biopsy approaches.
Using deleted codes like 55700 triggers immediate invalid-code rejections. Practices that updated their billing templates but not their documentation requirements — or that didn't verify their EHR removed the old code — are generating automatic denials on every prostate biopsy claim submitted under the old system.
The new biopsy code family also requires documentation specificity that wasn't needed before: the approach (transrectal vs. transperineal), whether the biopsy was systematic, targeted, or both, and the lesion characteristics when imaging guidance was used. Practices billing the new codes without matching documentation are creating a different risk: payment for a code that audit review can't support.
This is a two-sided coding transition that requires both billing system updates and documentation template updates simultaneously. The AUA itself noted it is revising the code set further for 2027 — meaning this coding area will continue evolving.
Magical's AI employees can validate that claims for prostate biopsy procedures are using 2026 codes with documentation that matches the required specificity — preventing both invalid-code rejections and underdocumented higher-tier claims.
2. Cystoscopy Supply Pack Reimbursement Drop — and the Reconciliation Gap
The 2026 CMS rule introduced a material change to the supply packs reimbursed alongside cystoscopy procedures. The cystoscopy visit pack (SA058) dropped from $94.68 to $75.67 — a 20% reduction phased in over four years, with the first reduction taking effect in 2026.
For high-volume cystoscopy practices, this is a predictable supply expense that no longer matches the reimbursement it was earning. Practices that haven't modeled this change against their actual cystoscopy volume don't know how large the margin impact is — and may be continuing to staff and price these cases as if the old supply reimbursement still applied.
This is a silent leak because the claim doesn't get denied. It pays — just at a lower rate that looks like a normal contractual adjustment unless someone is specifically watching the supply code remittance.
3. Diagnostic vs. Therapeutic Cystoscopy Coding Errors
Cystoscopy is one of urology's highest-volume procedures — and one of its most consistently miscoded.
The critical distinction: a diagnostic cystoscopy (CPT 52000) and a therapeutic cystoscopy are separate code families. If a therapeutic intervention is performed during the same scope session — a biopsy, a ureteral catheterization, a stone manipulation — the therapeutic code replaces the diagnostic code; they cannot be billed together. When both are submitted, the diagnostic code is denied as bundled.
The inverse error also occurs: therapeutic work is performed but only the diagnostic code is billed, because the documentation didn't clearly identify the additional intervention or the biller defaulted to the simpler code.
Both errors are systematic and predictable across high-volume practices that haven't built cystoscopy-specific code selection logic into their pre-submission validation.
4. Global Period Violations — Particularly on High-Volume Procedure Follow-Ups
Urology performs a significant volume of procedures with 10-day and 90-day global periods: TURBT, ureteroscopies, lithotripsies, prostatectomies, and others. Follow-up visits that fall within the global period require specific modifiers or are simply not separately billable.
The most common failures:
Post-procedure office visits billed without Modifier -24 (unrelated E/M during global period) or Modifier -79 (unrelated procedure)
Telehealth follow-ups for wound checks or symptom management after procedure billed as standard E/M within the global window
Follow-up visits by a physician of a different specialty than the surgeon billed incorrectly — an area CMS has been actively clarifying with new modifier guidance
For practices with high-volume surgical caseloads, global period violations generate both denial exposure and compliance exposure. The claims that do pay incorrectly during global periods are audit targets — payers increasingly use claim pattern analysis to identify global period unbundling.
Magical's AI employees can flag scheduled visits against active global periods at the time of booking — preventing the billing error before the encounter ever occurs.
5. Prior Authorization Failures on Imaging and Advanced Procedures
Urology's PA burden has grown substantially as payers tighten requirements for advanced imaging — MRI-guided prostate biopsies, PSMA PET scans, urodynamic studies — and as high-cost specialty medications require multi-step authorization.
Independent urology practices report no decline in PA workload despite announced "streamlining" initiatives, and in many cases report an increase in volume. Where PA failures generate the most damage in urology:
PSMA PET studies ordered for prostate cancer staging without PA, resulting in full claim denials on high-value imaging
Robotic prostatectomy authorizations that expire between the authorization date and the surgery date — particularly when surgical scheduling shifts
Biologics and specialty medications (including ADT agents and newer oncological therapies) where step therapy documentation is incomplete
High-cost lithotripsy and ureteroscopy procedures where prior auth was obtained but for a different laterality or approach than what was performed
The practices with the lowest PA-related denial rates treat authorization as a governed workflow — not a front-desk function that happens when there's time.
6. Ancillary Revenue Billing Complexity
Urology is one of the most ancillary-rich specialties in medicine. Many groups operate their own pathology labs, ambulatory surgery centers, lithotripsy services, radiation oncology programs, and in-office dispensing programs. More than 60% of urological procedures are currently performed in ambulatory settings.
Each ancillary service line has its own billing framework, supply codes, and compliance requirements — and the complexity multiplies when a single patient encounter involves the primary urology visit plus one or more ancillary services.
Common ancillary billing failures:
In-office pathology specimens billed without matching documentation of specimen collection and chain of custody
ASC facility fees with incorrect place-of-service codes that reduce reimbursement
Radiation oncology treatment management codes submitted without complete documentation of the week's treatment fraction count
Supply codes for IOD (in-office dispensing) programs billed without meeting state-specific compliance requirements for documentation
The practices that maximize ancillary revenue are those with distinct billing workflows for each service line — not shared billing staff applying general medical billing logic to specialty-specific codes.
7. Undercoding and E/M Complexity Suppression
Urology practices manage complex chronic disease patients — prostate cancer on active surveillance, patients with chronic urinary conditions, post-treatment oncology follow-ups. Many of these encounters support Level 4 or Level 5 E/M codes based on documented MDM complexity.
A consistent pattern: urologists document the complexity but code conservative E/M levels out of habit or audit caution. Across thousands of encounters annually, the cumulative revenue loss from systematic E/M undercoding is significant — and entirely preventable without any documentation change, only a coding review process that matches submitted levels to documented complexity.
Urology Revenue Doesn't Collapse — It Erodes
Most urology practices aren't facing a single catastrophic billing failure. They're facing seven simultaneous quiet ones: the deleted biopsy code transition, supply pack reimbursement drift, diagnostic/therapeutic cystoscopy confusion, global period violations, PA failures, ancillary billing complexity, and E/M undercoding.
Each is manageable in isolation. Together, with declining reimbursement as the backdrop, they represent a material financial risk that compounds month after month.
Magical's agentic AI employees are built for exactly this kind of work — claim-level precision across a high-complexity, high-volume billing environment, deployed in weeks with no IT integrations required.
Want to see where your biggest operational leaks are? Book a demo with our team to walk through a workflow assessment specific to your urology practice.